
Department of Pathology
Position: Professor
ORCID: 0000-0003-2184-1338
T +43 1 40400 36590
lukas.kenner@meduniwien.ac.at
Keywords
Prostate; Transcription Factor AP-1; Translational Medical Research
Research interests
- AP-1 and JAK-STAT signaling and core cancer pathways
- Basic and translational cancer research with a main focus on comparative pathology in human patient samples compared to gene targeted mouse models to explore new diagnostic approaches facilitating digital pathology procedures for establishing new therapies
Techniques, methods & infrastructure
Tissue micro arrays (TMA) of human patient samples, digital pathology, laboratory animal and translational pathology, transgenic mouse modelling, patient-derived grafts (PDX), organoid-derived grafts (ODX), CRISPR-Cas9, RNA knock-down strategies.
Molecular pathology methods (protein DNA and RNA analysis), in-vitro cell culture methods.
Grants
- CORE-LAB 2 for Target Identification and Probe Development (TIP) (2016)
Source of Funding: FFG (Austrian Research Promotion Agency), COMET: K1-Centres
Principal Investigator - PDGFRB function in lymphoma progression (2016)
Source of Funding: FWF (Austrian Science Fund), Stand alone projects
Principal Investigator - The European Research Initiative on Anaplastic Lymphoma Kinase (ALK)-related malignancies (2015)
Source of Funding: EU, H2020-MSCA-ITN-2015
Coordinator of the collaborative project - Genetic dissection of IL-6 signalling in prostate tumourigenesis (2013)
Source of Funding: FWF (Austrian Science Fund), Stand alone projects
Principal Investigator - Basic Funding of the LBI Cancer Research (2005)
Source of Funding: LBG (Ludwig Boltzmann Gesellschaft),
Principal Investigator
Selected publications
- Pencik, J. et al., 2015. STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nature Communications, 6, p.7736. Available at: http://dx.doi.org/10.1038/ncomms8736.
- Merkel, O. et al., 2015. Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. The Journal of Pathology, 236(4), pp.445-456. Available at: http://dx.doi.org/10.1002/path.4539.
- Laimer, D. et al., 2012. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Nature Medicine, 18(11), pp.1699-1704. Available at: http://dx.doi.org/10.1038/nm.2966.
- Merkel, O. et al., 2010. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proceedings of the National Academy of Sciences, 107(37), pp.16228-16233. Available at: http://dx.doi.org/10.1073/pnas.1009719107.
- Pflegerl, P. et al., 2009. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proceedings of the National Academy of Sciences, 106(48), pp.20423-20428. Available at: http://dx.doi.org/10.1073/pnas.0910371106.